You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 156 No. 12, 24 JUNE 1996 TABLE OF CONTENTS
  Archives
  •  Online Features
  ORIGINAL INVESTIGATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (45)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Risk of Acute Liver Injury Associated With the Combination of Amoxicillin and Clavulanic Acid

Luis A. García Rodríguez, MD, MSc; Bruno H. Stricker, MD; Hyman J. Zimmerman, MD

Arch Intern Med. 1996;156(12):1327-1332.


Abstract

Background
Amoxicillin—clavulanic acid combination— associated hepatitis and jaundice was first identified in 1988. Numerous case reports and case series have been published since then, but there is no precise estimate of this risk.

Methods
A retrospective cohort study in the United Kingdom to estimate the risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid and compare it with the one of amoxicillin alone. Data were derived from a cohort of 93 433 users of the combination drug amoxicillin—clavulanic acid and 360 333 users of amoxicillin alone who were aged between 10 and 79 years and who were followed up from 1991 through 1992. After reviewing the information on subjects with suspected liver injury that was recorded on computer files, the clinical records of 177 patients from the attending general practitioners were requested.

Results
They were 35 cases of idiopathic acute liver injury. None was fatal. There were 14 cases of acute liver injury among users of amoxicillin alone. The type of liver injury was hepatocellular in half the cases. There were 21 cases of acute liver injury among users of amoxicillin and clavulanic acid together. The type of liver injury was cholestatic in three quarters of the cases. The incidence rates and 95% confidence intervals (CIs) of developing acute liver injury associated with the combination of amoxicillin and clavulanic acid and amoxicillin alone were 1.7 (1.1-2.7) and 0.3 (0.2-0.5) per 10 000 prescriptions, respectively. The rate ratios and 95% CIs of acute liver injury for amoxicillin and clavulanic acid together compared with amoxicillin alone were 6.3 (3.2-12.7) for all patients and 8.4 (3.6-20.8) for patients presenting with jaundice. Among users of amoxicillin and clavulanic acid together, the risk of developing acute liver injury was more than 3 times greater after a course of 2 or more consecutive prescriptions than after a single course of therapy. The risk also increased with age among users of amoxicillin and clavulanic acid together. The combination of advancing age and repeated prescriptions resulted in a risk of developing acute liver injury greater than 1 per 1000 users of amoxicillin and clavulanic acid together.

Conclusions
Use of the combination of amoxicillin and clavulanic acid is associated with a higher incidence of acute hepatic injury than the use of amoxicillin alone. The injury is mostly cholestatic. The greatest absolute risk of developing acute liver injury in users of amoxicillin and clavulanic acid together is among elderly patients who are receiving continuous therapy.

(Arch Intern Med. 1996;156:1327-1332)



Author Affiliations

From the Centro Español de Investigación Farmacoepidemiológica, Universidad Complutense de Madrid, Madrid, Spain (Dr García Rodríguez), Department of Internal Medicine II, Academic Hopsital Dijkzigt, Rotterdam, and the Netherlands Center for Monitoring of Adverse Reactions to Drugs, Rijswijk (Dr Stricker), the Netherlands, and the Department of Medicine, The George Washington University Medical Center, and the American Registry of Pathology, Washington, DC (Dr Zimmerman).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Co-amoxiclav jaundice: clinical and histological features and HLA class II association
O'Donohue et al.
Gut 2000;47:717-720.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1996 American Medical Association. All Rights Reserved.